Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Company Deals

Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins

Fineline Cube May 19, 2026
Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial

Fineline Cube May 20, 2026
Company Drug

United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization

Fineline Cube May 20, 2026
Policy / Regulatory

Beijing Insurance Bureau Launches Pilot to Boost Access to NRDL Drugs

Fineline Cube Sep 28, 2023

The Beijing Municipal Medical Insurance Bureau has announced the initiation of pilot work aimed at...

Policy / Regulatory

Beijing-Tianjin-Hebei Region Initiates Drug VBP with 37 Medicines, Including Biologics

Fineline Cube Sep 28, 2023

The Beijing Municipal Medical Insurance Bureau has issued a notification to commence the drug volume-based...

Company Deals

Regeneron Pharmaceuticals Acquires Decibel Therapeutics to Advance Hearing Loss Treatments

Fineline Cube Sep 27, 2023

Regeneron Pharmaceuticals (NASDAQ: REGN) has completed the acquisition of Decibel Therapeutics, a developer of gene...

Company Deals

Novo Nordisk Partners with Valo Health to Develop Cardiometabolic Disease Therapies

Fineline Cube Sep 27, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a strategic partnership with US company...

Company Drug

Coherus Biosciences Awaits FDA Decision on Toripalimab with Year-End Approval Forecast

Fineline Cube Sep 27, 2023

Coherus Biosciences Inc., (NASDAQ: CHRS), a US-based biotechnology company, has provided an update on the...

Company Drug

Cutia Therapeutics Files for Market Approval of CU-10201 with NMPA for Acne Treatment

Fineline Cube Sep 27, 2023

Cutia Therapeutics (HKG: 2487), a developer focused on dermatology therapies, has announced the submission of...

Drug

United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment

Fineline Cube Sep 27, 2023

United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced that...

Company Drug

BioTroy Therapeutics Receives US FDA IND Approval for Anti-Tumor Drug BT02

Fineline Cube Sep 27, 2023

BioTroy Therapeutics, a Shanghai-based developer of cancer immunotherapies, has announced the receipt of Investigational New...

Company Drug

Sichuan Kelun-Biotech’s KL-A167 and SKB264 Gain Tacit Clinical Trial Approval in China

Fineline Cube Sep 27, 2023

The Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...

Company

Sino Biopharmaceutical Reports H1 2023 Revenue Growth, Focus on Innovative Drugs

Fineline Cube Sep 27, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has released its financial report...

Company Deals

Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership

Fineline Cube Sep 27, 2023

Suzhou Novoprotein Scientific Co., Ltd, (SHA: 688137) a leading provider of protein technology and application...

Company

Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus

Fineline Cube Sep 27, 2023

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first...

Company Medical Device

CIRC Unveils FuZhi 1.0 Smart Nuclear Medicine System at Chinese Medical Association Meeting

Fineline Cube Sep 27, 2023

China Isotope & Radiation Corporation (CIRC; HKG: 1763) has announced the launch of its innovative...

Policy / Regulatory

Hunchun Port Designated as Medical Materials Import Port by NMPA and GAC

Fineline Cube Sep 27, 2023

The National Medical Products Administration (NMPA) and the General Administration of Customs have jointly released...

Company

Baxter Appoints Wu Xin as China General Manager Amid Spin-Off of Kidney Care Business

Fineline Cube Sep 27, 2023

Baxter (NYSE: BAX), a leading provider of healthcare products, has announced the appointment of Wu...

Company

China Grand Pharmaceutical Reports H1 2023 Revenues and Pipeline Progress

Fineline Cube Sep 27, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has released its financial report...

Company Drug

EC Approves AbbVie’s Tepkinly for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Fineline Cube Sep 26, 2023

The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its bispecific...

Company Drug

Sanofi’s Altuviiio Receives Marketing Approval from Japan’s MHLW for Hemophilia A Treatment

Fineline Cube Sep 26, 2023

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...

Company

Lepu ScienTech Reports 33% Revenue Growth in 2023 Interim Report

Fineline Cube Sep 26, 2023

Lepu ScienTech Medical Technology (Shanghai) Co., Ltd, (HKG: 2291) a China-based medical technology company, has...

Company Drug

Japan’s MHLW Approves Eisai and BioArctic’s Leqembi for Alzheimer’s Treatment

Fineline Cube Sep 26, 2023

The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted approval to Eisai...

Posts pagination

1 … 469 470 471 … 668

Recent updates

  • Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo
  • Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial
  • UCB’s BIMZELX Demonstrates Superior Joint Outcomes vs SKYRIZI in Phase III BE BOLD Trial for Psoriatic Arthritis
  • United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization
  • ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Company Drug

Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial

Others

UCB’s BIMZELX Demonstrates Superior Joint Outcomes vs SKYRIZI in Phase III BE BOLD Trial for Psoriatic Arthritis

Company Drug

United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.